Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Shots:

• Isomorphic Labs has reported a $2.1B Series B financing round led by Thrive Capital, with participation from existing investors Alphabet & GV alongside new backers MGX, Temasek, CapitalG, & the UK Sovereign AI Fund
• The company plans to use the capital to further develop & deploy its AI-powered drug discovery platform, IsoDDE, accelerate internal therapeutic programs toward the clinic, and expand hiring across AI, engineering, drug design & clinical development functions
• Isomorphic also highlighted the predictive accuracy & expanded capabilities of IsoDDE, showcasing advances that bridge structure prediction with real-world drug discovery, while also advancing AI-driven drug discovery collaborations with Novartis, Eli Lilly, and J&J

Ref: Isomorphic Labs  |  Image: Isomorphic Labs  | Press Release

Related News: Roche’ Elecsys pTau217 Test Receives the European CE Mark Approval to Rule in or Rule Out Alzheimer’s-Related Amyloid Pathology

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com